Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
TYShcsdePMYanS0p
